Saurashtra News

Polymyalgia Rheumatica Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Roche, Abatacept, Eli-lilly

 Breaking News
  • No posts were found

Polymyalgia Rheumatica Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Roche, Abatacept, Eli-lilly

March 15
23:44 2023
Polymyalgia Rheumatica Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Roche, Abatacept, Eli-lilly
The Polymyalgia Rheumatica market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyalgia Rheumatica pipeline products will significantly revolutionize the Polymyalgia Rheumatica market dynamics.

DelveInsight’s “Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Polymyalgia Rheumatica, historical and forecasted epidemiology as well as the Polymyalgia Rheumatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Polymyalgia Rheumatica market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Polymyalgia Rheumatica market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyalgia Rheumatica Market Insights

 

Polymyalgia Rheumatica Overview

Polymyalgia rheumatica (PMR) is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). PMR can be a relatively benign condition that is extremely responsive to treatment.

 

Some of the key facts of the Polymyalgia Rheumatica Market Report: 

  • The Polymyalgia Rheumatica market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to Duncan et al. the estimated prevalence of PMR, in the United States, is 1 in 133 people over the age of 50 years. The incidence of PMR and GCA increases with age, with a peak in those 70–80 years of age
  • According to Crowson ‘et al’ women accounted for 65 to 75% of patients. Polymyalgia rheumatica occurs at a frequency that is 3 to 10 times that of giant-cell arteritis
  • A study by E. Machedo et al. of biopsy-proven GCA demonstrated an average annual incidence and prevalence of 17 and 223, respectively per 100,000 population aged 50 years or more cases in Scandinavian countries and northwestern Spain
  • Key Polymyalgia Rheumatica Companies: Bristol-Myers Squibb, AbbVie, Eli Lilly and Company, Sparrow Pharmaceuticals, and others
  • Key Polymyalgia Rheumatica Therapies: Tocilizumab, Bristol Myers Squibb, Baricitinib, and others

 

Get a Free sample for the Polymyalgia Rheumatica Market Report –

https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market

 

Key benefits of the Polymyalgia Rheumatica Market report:

  1. Polymyalgia Rheumatica market report covers a descriptive overview and comprehensive insight of the Polymyalgia Rheumatica Epidemiology and Polymyalgia Rheumatica market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Polymyalgia Rheumatica market report provides insights on the current and emerging therapies.
  3. Polymyalgia Rheumatica market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Polymyalgia Rheumatica market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Polymyalgia Rheumatica market.

 

Download the report to understand which factors are driving Polymyalgia Rheumatica epidemiology trends @ Polymyalgia Rheumatica Epidemiological Insights 

 

Polymyalgia Rheumatica Market  

The dynamics of the Polymyalgia Rheumatica market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The corticosteroid drug deflazacort is being studied for the treatment of polymyalgia rheumatic (PMR). Deflazacort may be an effective alternative to prednisone and may also have fewer side effects. More studies are needed to determine the long-term safety and effectiveness of this drug to treat PMR.”

 

Polymyalgia Rheumatica Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Polymyalgia Rheumatica Epidemiology Segmentation:

The Polymyalgia Rheumatica market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Polymyalgia Rheumatica
  • Prevalent Cases of Polymyalgia Rheumatica by severity
  • Gender-specific Prevalence of Polymyalgia Rheumatica
  • Diagnosed Cases of Episodic and Chronic Polymyalgia Rheumatica

 

Polymyalgia Rheumatica Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyalgia Rheumatica market or expected to get launched during the study period. The analysis covers Polymyalgia Rheumatica market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyalgia Rheumatica Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Polymyalgia Rheumatica market share @ Polymyalgia Rheumatica market forecast 

 

Polymyalgia Rheumatica Therapies and Key Companies

  • Tocilizumab: Roche
  • Bristol Myers Squibb: Abatacept
  • Baricitinib: Eli-lilly

 

Scope of the Polymyalgia Rheumatica Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Polymyalgia Rheumatica Companies: Bristol-Myers Squibb, AbbVie, Eli Lilly and Company, Sparrow Pharmaceuticals, and others
  • Key Polymyalgia Rheumatica Therapies: Tocilizumab, Bristol Myers Squibb, Baricitinib, and others
  • Polymyalgia Rheumatica Therapeutic Assessment: Polymyalgia Rheumatica current marketed and Polymyalgia Rheumatica emerging therapies
  • Polymyalgia Rheumatica Market Dynamics: Polymyalgia Rheumatica market drivers and Polymyalgia Rheumatica market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Polymyalgia Rheumatica Unmet Needs, KOL’s views, Analyst’s views, Polymyalgia Rheumatica Market Access and Reimbursement 

 

Table of Contents 

1. Polymyalgia Rheumatica Market Report Introduction

2. Executive Summary for Polymyalgia Rheumatica

3. SWOT analysis of Polymyalgia Rheumatica

4. Polymyalgia Rheumatica Patient Share (%) Overview at a Glance

5. Polymyalgia Rheumatica Market Overview at a Glance

6. Polymyalgia Rheumatica Disease Background and Overview

7. Polymyalgia Rheumatica Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyalgia Rheumatica 

9. Polymyalgia Rheumatica Current Treatment and Medical Practices

10. Polymyalgia Rheumatica Unmet Needs

11. Polymyalgia Rheumatica Emerging Therapies

12. Polymyalgia Rheumatica Market Outlook

13. Country-Wise Polymyalgia Rheumatica Market Analysis (2019–2032)

14. Polymyalgia Rheumatica Market Access and Reimbursement of Therapies

15. Polymyalgia Rheumatica Market Drivers

16. Polymyalgia Rheumatica Market Barriers

17.  Polymyalgia Rheumatica Appendix

18. Polymyalgia Rheumatica Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Polymyalgia Rheumatica treatment, visit @ Polymyalgia Rheumatica Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles